Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

Monte Rosa Therapeutics (Nasdaq: GLUE) will present interim clinical results for the NEK7-directed molecular glue degrader MRT-8102 on Jan 7, 2026 at 8:00 a.m. ET.

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE) will present interim clinical results for the NEK7-directed molecular glue degrader MRT-8102 on Jan 7, 2026 at 8:00 a.m. ET. The presentation will highlight interim data from the ongoing Phase 1 study, including the Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk.

The event will be available via live conference call and webcast through the company’s Events & Presentations page at ir.monterosatx.com, with an archived webcast accessible for 30 days after the presentation.

Argus Jan 7 session

+45.41% close to close Open Argus

Details

News Market Reaction – GLUE

On Jan 7, the first trading day after this news, GLUE closed 45.41% above the previous close.

Data tracked by StockTitan Argus for the Jan 7 session.

Key Figures

Phase: Phase 1 Study part: Part 3 Cohort focus: Elevated cardiovascular disease risk +3 more

Phase

Phase 1

Ongoing MRT-8102 study

Study part

Part 3

CRP proof-of-concept cohort

Cohort focus

Elevated cardiovascular disease risk

MRT-8102 Part 3 subjects

Webcast time

8:00 a.m. ET

Conference call on January 7, 2026

Webcast date

January 7, 2026

Interim MRT-8102 Phase 1 presentation

Archive period

30 days

Archived webcast availability

Historical Context

5 past events · Latest: Dec 16

5 events

1. Dec 16

   Clinical data update

   24h Move

   +13.4%

   Interim Phase 1/2 MRT-2359 combo data showed strong activity and control rates.

2. Dec 15

   Clinical update scheduling

   24h Move

   +0.9%

   Announcement of webcast to present updated MRT-2359 Phase 1/2 interim results.

3. Nov 06

   Earnings and partnership

   24h Move

   +5.7%

   Q3 2025 results with Novartis deal, strong cash and multiple advancing programs.

4. Nov 03

   Investor conferences

   24h Move

   -6.1%

   Participation in several investor conferences without new clinical or financial data.

5. Oct 24

   Preclinical data

   24h Move

   +7.3%

   Preclinical MRT-6160 data showing broad activity and disease reduction signals.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molecular glue degrader, nek7-directed, crp

3 terms

molecular glue degrader medical

"a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines"

A molecular glue degrader is a small drug-like molecule that acts like a tiny adhesive, sticking a specific disease-related protein to the cell’s natural disposal machinery so the protein is destroyed rather than merely blocked. Investors watch these compounds because they can turn previously untreatable targets into removable liabilities, potentially creating breakthrough therapies, shifting development risk, and offering strong commercial upside if clinical results and regulatory approval follow.

nek7-directed medical

"Phase 1 study of the NEK7-directed MGD MRT-8102"

NEK7-directed describes drugs, biologics or research tools designed to specifically target the NEK7 protein, a cellular regulator involved in cell division and inflammatory signaling. Investors should care because agents that precisely block or modulate a single protein can lead to new therapies with clearer benefits or risks, shaping clinical trial outcomes, regulatory decisions and commercial potential—think of fixing one gear in a machine to stop a malfunction without breaking the whole device.

crp medical

"Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk"

CRP stands for C-reactive protein, a substance produced by the liver that appears in the blood when the body has inflammation or infection. Think of it like a smoke detector for inflammation: higher CRP levels signal that something is triggering an immune response. Investors watch CRP because it’s often used as a clinical marker in drug trials and diagnostics, can affect regulatory decisions and market demand for therapies or tests, and therefore can influence a company’s clinical and commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call and webcast to be held at 8 a.m. ET on January 7, 2026

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD MRT-8102, including interim data from the ongoing Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk.

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Monte Rosa Therapeutics (GLUE) present interim MRT-8102 Phase 1 results?

The company will present on January 7, 2026 at 8:00 a.m. ET via live conference call and webcast.

What data will Monte Rosa share about MRT-8102 in the Jan 7, 2026 presentation?

The presentation will highlight interim Phase 1 results, including Part 3 CRP proof-of-concept cohort data in subjects with elevated cardiovascular risk.

How can investors access the Monte Rosa webcast for GLUE’s MRT-8102 update?

Access the live webcast and conference call via the company’s Events & Presentations page at ir.monterosatx.com; registration link is provided there.

Will the MRT-8102 presentation webcast be available after the live event?

Yes, an archived version of the webcast will be available for 30 days following the presentation.

What is the focus of the Part 3 CRP cohort mentioned for MRT-8102?

The Part 3 cohort is a CRP proof-of-concept cohort studying subjects with elevated cardiovascular disease risk.